ArticleClinical rheumatology2026
Retrospective analysis of myositis-specific antibody-positive veteran survival between 2011 and 2023.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe rarity of myositis-specific antibodies (MSAs) presents challenges in the assessment of idiopathic inflammatory myopathy (IIM) subsets. We leveraged a national database to identify MSA-positive veterans and compare all-cause mortality across antibody subsets in a singular population.
methodsA retrospective analysis of veteran adults with MSA testing between 1/1/2011 and 12/31/2021 was performed. A minimum of two outpatient International Classification of Disease 9 or 10 visit codes from specialty clinics at least 30 days apart with one creatine phosphokinase level above the upper limit of normal was used to assign a presumptive IIM diagnosis. Current Procedural Terminology codes were used to identify lung computerized tomography imaging studies. Kaplan-Meier survival and Cox proportional regression analyses were performed for the primary outcome of mortality from any cause with a censor date of 12/10/2023.
resultsA total of 1749 veterans met inclusion criteria. Jo-1 was the most common MSA (75.0%), followed by PL-7 (8.9%) and HMGCR (3.5%). Our cohort was male-predominant (83.4%) with a robust representation of non-White veterans (47.3%). Jo-1 individuals had longer survival compared to non-Jo-1 (75% survival at 6.5 years, 95% CI 5.8-7.1 vs 3.4 years, 95% CI 2.7-5.2, log rank p < 0.001). Univariate and multivariable Cox proportional hazard analyses showed that non-Jo-1 status was associated with higher mortality, irrespective of antibody titer. There were no sex differences in mortality or lung disease prevalence.
conclusionsAge, lung involvement, and non-Jo-1 MSA status are associated with increased veteran mortality in this large, male-predominant cohort. Key Points • Jo-1 antibody positivity was associated with the best survival among MSA subsets. • The incidence of lung involvement was equal among Jo-1-positive men and women. • Veteran survival was chiefly determined by MSA subtype, irrespective of antibody titer.
Indexed as
Identifiers
41291379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.